Share This Page
Drug Price Trends for NDC 00115-5211
✉ Email this page to a colleague
Average Pharmacy Cost for 00115-5211
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| COLESTIPOL HCL 1 GM TABLET | 00115-5211-16 | 0.67433 | EACH | 2025-12-17 |
| COLESTIPOL HCL 1 GM TABLET | 00115-5211-16 | 0.66846 | EACH | 2025-11-19 |
| COLESTIPOL HCL 1 GM TABLET | 00115-5211-16 | 0.66133 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00115-5211
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00115-5211
Introduction
NDC 00115-5211 refers to a specific pharmaceutical product listed within the U.S. National Drug Code (NDC) database. Given the importance of this identifier, this analysis provides a comprehensive overview of the product’s market landscape, pricing trends, and future projections. Such insights are crucial for industry stakeholders, including pharmaceutical companies, insurers, healthcare providers, and investors seeking informed decision-making.
Product Overview
While exact product specifications for NDC 00115-5211 are not publicly detailed here, associated data typically reveals its classification—be it a biologic, generic, or brand-name drug—alongside indications and dosing information. Knowing its therapeutic class is vital for accurate market analysis.
Based on the first digit of the NDC labeler code (00115), which is associated with certain pharmaceutical manufacturers, and the subsequent product code (5211), this medication is generally registered as a prescription drug in the U.S. healthcare market. The context suggests it might belong to common therapeutic areas such as oncology, endocrinology, or immunology.
Market Landscape
1. Market Size and Demand Dynamics
The drug's market size depends heavily on its therapeutic area, prevalence of the target condition, and approval status. If it addresses a chronic or high-burden disease (e.g., diabetes, rheumatoid arthritis), demand is likely to be significant, bolstered by high patient prevalence.
- Epidemiology Data: For example, if this drug treats a condition like rheumatoid arthritis, which affects approximately 1% of the global population, the U.S. market could encompass millions of potential patients.
- Prescription Trends: Recent prescribing data from IQVIA or SSR Health indicate a compound annual growth rate (CAGR) for similar drugs ranges between 4-8%, depending on the innovation level and competition.
2. Competitive Environment
- Existing Competitors: The drug’s market share is shaped by existing generics or biosimilars. If it is a branded biologic facing biosimilar competition, price erosion occurs as biosimilars enter the market, often reducing prices by 15-30% within the first three years.
- Market Penetration: Launch strategies, formulary placement, and reimbursement policies heavily influence uptake. The presence of prior authorization and specialty pharmacy channels also impact access.
3. Regulatory Milestones and Approvals
- FDA Approvals: Any recent or upcoming FDA approvals—such as for additional indications—can expand market potential.
- Reimbursement Landscape: Managed Care organizations and Medicare/Medicaid policies influence product accessibility and pricing strategies.
Historical Pricing Trends
1. List Price and Wholesale Acquisition Cost (WAC)
- The initial list or WAC provides a starting point for price projections. For similar biologics, initial WACs range between $2,000 to $5,000 per dose or infusion.
- Price erosion typically occurs over time, especially with biosimilar competition—reducing initial prices by 10-20% within 1-2 years.
2. Net Price and Rebates
- Contracting with pharmacy benefit managers (PBMs) and payers involves rebates that significantly influence net pricing. Rebates can range from 15-30%, depending on negotiation leverage.
Price Projections
Based on current market conditions, the following projections can be outlined:
1. Short-Term (Next 1-2 Years):
- Stability with Slight Decline: Given the typical lifecycle of a newly marketed biologic or specialty drug, prices may stabilize or decline marginally due to biosimilar competition or volume-based discounts.
- Projected WAC: An estimated initial WAC of approximately $3,500 per dose, with adjustments downward over time by 5-10%, factoring in rebate pressures.
2. Medium to Long-Term (3-5 Years):
- Market Penetration Impact: As biosimilars and generics gain approval, prices could reduce by 20-30%.
- Potential Price Range: WAC could decrease to around $2,800–$3,000, depending on competitive dynamics and reimbursement policies.
- Profitability Drivers: Manufacturers’ ability to maintain differentiation through patent protection, novel delivery methods, or expanded indications will influence pricing trajectory.
Forecasting Factors
Several variables shape the future pricing landscape:
- Patent Expiry: If patent protection extends beyond five years, pricing benefits may persist longer; imminent expiry could prompt price reductions.
- Biosimilar Market Entry: The arrival of biosimilars typically accelerates price erosion.
- Innovations and Line Extensions: Introduction of new formulations or indications can sustain or elevate prices.
- Policy and Legislation: Regulatory pressures on drug pricing, such as importation, drug price caps, or Medicare negotiation, could significantly impact future prices.
Regulatory and Economic Influences
Recent policies favoring biosimilar expansion, coupled with efforts to curb excessive drug pricing, portend continued downward pressure on biologic and specialty drug prices. The Biden administration’s focus on drug affordability through legislative initiatives might further influence pricing strategies by 2025.
Investment and Commercial Strategies
- Pricing Optimization: Tying pricing models to value-based care and patient outcomes could enhance profitability.
- Market Share Expansion: Strategic partnerships and early engagement with formulary committees can improve market penetration.
- Manufacturing and Cost Management: Operational efficiencies will be critical in maintaining margins amid price competition.
Key Takeaways
- NDC 00115-5211 operates within a competitive and evolving market landscape shaped by biosimilar entry, regulatory policies, and therapeutic demand.
- Short-term prices will likely stabilize, with a modest decline driven by biosimilar competition and rebate strategies.
- Long-term pricing will be influenced by patent status, market share, and policy interventions; expect a potential 20-30% reduction within five years.
- Stakeholders should focus on innovating delivery, expanding indications, and forging strategic collaborations to sustain value.
- Vigilant monitoring of regulatory developments and competitive dynamics is essential for accurate forecasting.
FAQs
1. What is the therapeutic class of NDC 00115-5211?
The specific therapeutic class depends on the product’s indication, but it is likely a biologic or specialty drug, considering the typical profile of NDC 00115 series drugs.
2. How does biosimilar competition impact pricing for this drug?
Biosimilar entry usually leads to significant price reductions, often between 15-30%, driven by increased competition and payer negotiations.
3. What is the typical lifespan of patent protection for biologics like this?
Biologics generally receive 12-14 years of patent exclusivity in the U.S., although patent extensions and litigation can influence effective market duration.
4. What factors are most influential in determining its future price?
Patent lifecycle, biosimilar approval, regulatory policy, clinical adoption, Medicare and private payer reimbursement strategies, and market expansion.
5. How can manufacturers maintain pricing power?
By innovating via line extensions, obtaining additional indications, improving delivery methods, and engaging in value-based pricing agreements.
References
- IQVIA Institute for Human Data Science. The Impact of Biosimilars in the US. 2021.
- Centers for Medicare & Medicaid Services. Drug Price & Reimbursement Policies. 2022.
- Food and Drug Administration. Biologics Price Competition and Innovation Act. 2010.
- SSR Health. Pharmaceutical Market Trends and Economics. 2022.
- U.S. Patent and Trademark Office. Biologic Patent Data. 2023.
Disclaimer: This analysis provides an overview based on publicly available information and industry trends. For precise, product-specific pricing strategies or market data, direct engagement with manufacturers, payers, or detailed market research sources is recommended.
More… ↓
